Chemistry:MK-608
 | |
| Clinical data | |
|---|---|
| Other names | 7-Deaza-2’-C-methyladenosine; 7DMA |
| Legal status | |
| Legal status | |
| Identifiers | |
| |
| CAS Number | |
| PubChem CID | |
| ChemSpider | |
| UNII | |
| Chemical and physical data | |
| Formula | C12H16N4O4 |
| Molar mass | 280.284 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
MK-608 (7-deaza-2’-C-methyladenosine, 7DMA) is an antiviral drug, an adenosine analog (a type of nucleoside analog). It was originally developed by Merck & Co. as a treatment for hepatitis C, but despite promising results in animal studies,[1][2] it was ultimately unsuccessful in clinical trials.[3] Subsequently it has been widely used in antiviral research and has shown activity against a range of viruses, including Dengue fever,[4] tick-borne encephalitis virus,[5] poliovirus,[6][7] and most recently Zika virus,[8][9] in both in vitro and animal models. Since it has already failed in human clinical trials previously, it is unlikely MK-608 itself will be developed as an antiviral medication, but the continuing lack of treatment options for these emerging viral diseases means that much research continues using MK-608 and related antiviral drugs.[10]
See also
References
- ↑ "Robust antiviral efficacy upon administration of a nucleoside analog to hepatitis C virus-infected chimpanzees". Antimicrobial Agents and Chemotherapy 53 (3): 926–34. March 2009. doi:10.1128/AAC.01032-08. PMID 19075052.
- ↑ "Sustained viral response in a hepatitis C virus-infected chimpanzee via a combination of direct-acting antiviral agents". Antimicrobial Agents and Chemotherapy 55 (2): 937–9. February 2011. doi:10.1128/AAC.00990-10. PMID 21115793.
- ↑ "Sensitivity of mitochondrial transcription and resistance of RNA polymerase II dependent nuclear transcription to antiviral ribonucleosides". PLOS Pathogens 8 (11): e1003030. 2012. doi:10.1371/journal.ppat.1003030. PMID 23166498.
- ↑ "A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs". The Journal of Infectious Diseases 195 (5): 665–74. March 2007. doi:10.1086/511310. PMID 17262707.
- ↑ "Nucleoside inhibitors of tick-borne encephalitis virus". Antimicrobial Agents and Chemotherapy 59 (9): 5483–93. September 2015. doi:10.1128/AAC.00807-15. PMID 26124166.
- ↑ "2'-C-methylcytidine as a potent and selective inhibitor of the replication of foot-and-mouth disease virus". Antiviral Research 73 (3): 161–8. March 2007. doi:10.1016/j.antiviral.2006.09.007. PMID 17055073.
- ↑ "Synthesis of a 6-methyl-7-deaza analogue of adenosine that potently inhibits replication of polio and dengue viruses". Journal of Medicinal Chemistry 53 (22): 7958–66. November 2010. doi:10.1021/jm100593s. PMID 20964406.
- ↑ "Nucleoside Inhibitors of Zika Virus". The Journal of Infectious Diseases 214 (5): 707–11. September 2016. doi:10.1093/infdis/jiw226. PMID 27234417.
- ↑ "The Viral Polymerase Inhibitor 7-Deaza-2'-C-Methyladenosine Is a Potent Inhibitor of In Vitro Zika Virus Replication and Delays Disease Progression in a Robust Mouse Infection Model". PLOS Neglected Tropical Diseases 10 (5): e0004695. May 2016. doi:10.1371/journal.pntd.0004695. PMID 27163257.
- ↑ "Antiviral properties of deazaadenine nucleoside derivatives". Current Medicinal Chemistry 13 (29): 3529–52. 2006. doi:10.2174/092986706779026228. PMID 17168721.
 |  |
